Ubs Group Ag Cidara Therapeutics, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Cidara Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 4,695 shares of CDTX stock, worth $59,579. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,695

Holding current value

$59,579

% of portfolio

0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.64 - $0.92 $3,004 - $4,319	4,695 New	4,695 $4,000
Q2 2022 Aug 10, 2022	SELL	$0.43 - $0.91 $737 - $1,559	-1,714 Reduced 99.36%	11 $0
Q1 2022 May 16, 2022	BUY	$0.67 - $1.39 $1,148 - $2,382	1,714 Added 15581.82%	1,725 $1,000
Q4 2021 Feb 14, 2022	SELL	$1.18 - $2.18 $4 - $8	-4 Reduced 26.67%	11 $0
Q3 2021 Nov 15, 2021	SELL	$1.48 - $2.35 $8,851 - $14,055	-5,981 Reduced 99.75%	15 $0

Q2 2021 Aug 13, 2021	SELL	$1.87 - $2.7 $32,020 - $46,232	-17,123 Reduced 74.06%	5,996 $12,000
Q1 2021 May 12, 2021	SELL	$2.06 - $3.01 $3,949 - $5,770	-1,917 Reduced 7.66%	23,119 $62,000
Q4 2020 Feb 11, 2021	SELL	$1.99 - $3.25 $257,108 - $419,900	-129,200 Reduced 83.77%	25,036 $50,000
Q3 2020 Nov 12, 2020	BUY	$2.85 - $4.1 $37,508 - $53,960	13,161 Added 9.33%	154,236 $440,000
Q2 2020 Jul 31, 2020	BUY	$2.39 - $4.0 $253,889 - $424,920	106,230 Added 304.86%	141,075 $520,000
Q1 2020 May 01, 2020	BUY	$1.74 - $4.26 $56,033 - $137,184	32,203 Added 1218.89%	34,845 $87,000
Q4 2019 Feb 14, 2020	SELL	$1.77 - $3.84 $11,352 - $24,629	-6,414 Reduced 70.83%	2,642 $10,000
Q3 2019 Nov 14, 2019	BUY	$1.25 - $2.35 $413 - $777	331 Added 3.79%	9,056 $18,000
Q2 2019 Aug 14, 2019	SELL	$1.49 - $2.94 $3,200 - $6,315	-2,148 Reduced 19.76%	8,725 $14,000
Q1 2019 May 14, 2019	BUY	$2.35 - $3.27 $3,362 - $4,679	1,431 Added 15.16%	10,873 $29,000
Q4 2018 Feb 14, 2019	BUY	$2.1 - $4.5 $10,086 - $21,613	4,803 Added 103.54%	9,442 $22,000
Q3 2018 Nov 14, 2018	SELL	$3.7 - $5.25 $9,590 - $13,608	-2,592 Reduced 35.85%	4,639 $20,000
Q2 2018 Aug 14, 2018	BUY	$3.75 - $6.05 $12,596 - $20,321	3,359 Added 86.75%	7,231 $38,000
Q1 2018 May 15, 2018	BUY	$4.0 - $8.15 $9,888 - $20,146	2,472 Added 176.57%	3,872 $15,000
Q4 2017 Feb 14, 2018	BUY	$6.35 - $8.75 $8,890 - $12,250	1,400 New	1,400 $10,000
Q3 2017 Nov 14, 2017	SELL	$5.75 - $8.1 $799 - $1,125	-139 Closed	0 $0
Q2 2017 Aug 14, 2017	SELL	N/A	-1,176 Reduced 89.43%	139 $1,000
Q1 2017 Nov 14, 2017	BUY	N/A	1,315	1,315 $10,000

Others Institutions Holding CDTX

# of Institutions

Shares Held

22.1M

Call Options Held

2.7K

Put Options Held

100

Bvf Inc San Francisco, CA

6.86M
Shares

$87.1 Million
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

3.35M
Shares

$42.5 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

2.55M
Shares

$32.4 Million
0.0% of portfolio
Alethea Capital Management, LLC San Diego, CA

1.6M
Shares

$20.3 Million
1.21% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

1.25M
Shares

$15.9 Million
0.0% of portfolio

View Full List

About Cidara Therapeutics, Inc.

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $889M
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

More about CDTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account